Teewinot gets US patent for bioreactor used to make synthetic cannabinoid APIs

By Gareth Macdonald

- Last updated on GMT


Related tags Active ingredient Pharmacology

Teewinot Life Sciences has been granted a US patent for a bioreactor it uses to produce synthetic cannabinoids.

The patent​ covers the bioreactor and control technology in which Teewinot cultures bacteria that produce the enzymes it uses to make synthetic cannabinoids.

These cannabinoids - specifically tetrahydrocannabinolic acid (THCA), cannabichromenic acid (CBCA), cannabidiolic acid (CBDA) and cannabichromenic acid (CBCA) - are processed into active pharmaceutical ingredients (APIs).

Spokesman Eric Walker told us “the bioreactor is uniquely designed for the production of cannabiniods using our company’s patent protected biosynthetic processes​” adding that the technology was developed by an in-house team.

Teewinot will use the technology to make APIs for the drug industry, however, it will also license the system to third parties according to Walker.

The bioreactor could be used to manufacture non-cannabinoid APIs but our company is focused on production and therapies based on manufacture of authentic cannabinoids, cannabinoid pro-drugs and cannabinoid analogs​.”

IP portfolio

The new patent – which was awarded to Teewinot’s Ireland based subsidiary Full Spectrum Laboratories – is the second the US firm has been granted in as many months.

The previous patent covers the production process, which uses enzymes made in genetically modified bacteria to produce enzymes that convert starting materials into cannabinoids.

The process patent was licensed by Nemus Biosciences last month​.

According to CEO Jeffrey Korentur Teewinot is collaborating with AMRI –Nemus’ current API supplier – to scale-up the cannabinoid production process.

Korentur told us last month that: “Our scale up is in progress now, and we anticipate being able to produce kilogram quantities of GMP manufactured cannabinoids by Q1 2017​.”

Related news

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more